PREDNICEN-M
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PREDNICEN-M (PREDNICEN-M).
Prednicen-M is a glucocorticoid that binds to the glucocorticoid receptor (GR), leading to altered gene expression. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production (e.g., IL-1, IL-2, TNF-alpha). It also induces lipocortin synthesis, which inhibits arachidonic acid release.
| Metabolism | Metabolized in the liver via CYP3A4 (major) and other CYP enzymes. Prednicen-M is a prodrug of prednisolone. |
| Excretion | Renal: ~80% as metabolites and unchanged drug (primarily as 17-ketosteroids and glucuronide conjugates); fecal: <5%; biliary: minor. |
| Half-life | 2-3 hours (prednisone); terminal half-life of prednisolone is 2-4 hours in normal renal function, prolonged to 3-4 hours in renal impairment, and may be extended in hepatic impairment. |
| Protein binding | Prednisolone: 70-90% bound to corticosteroid-binding globulin (CBG, transcortin) and albumin; prednisone: approximately 70% bound to CBG and albumin. |
| Volume of Distribution | 0.5-1.2 L/kg (prednisolone); the high Vd indicates extensive tissue distribution, particularly to liver, kidney, and adipose tissue. |
| Bioavailability | Oral: 70-85% (prednisone is rapidly converted to prednisolone in liver; bioavailability is dose-dependent and slightly reduced by food). |
| Onset of Action | Oral: 1-2 hours (glucocorticoid effect); IV: within 1 hour; IM: 1-2 hours (assuming prednisone conversion to prednisolone). |
| Duration of Action | 12-36 hours (pituitary-adrenal suppression lasting up to 36 hours); clinical duration of anti-inflammatory effects is 12-24 hours after single dose. |
| Molecular Weight | 360.44 |
Oral, 5-60 mg/day divided every 6-12 hours, adjusted based on disease severity and response.
| Dosage form | TABLET |
| Renal impairment | GFR ≥50 mL/min: no adjustment; GFR 10-49 mL/min: no adjustment; GFR <10 mL/min: no adjustment; hemodialysis: supplemental dose not required. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 75%. |
| Pediatric use | Oral, 0.14-2 mg/kg/day divided every 6-12 hours, maximum 60 mg/day. |
| Geriatric use | Start at lowest effective dose (e.g., 5 mg/day) and titrate slowly due to increased risk of osteoporosis, hypertension, and glucose intolerance. |
| 1st trimester | Prednisolone (active metabolite of prednisone) crosses the placenta; first-trimester use may increase risk of oral clefts (odds ratio ~3.4). Use only if clearly needed. |
| 2nd trimester | Second-trimester exposure associated with potential for fetal growth restriction and adrenal suppression. Assess risk-benefit. |
| 3rd trimester | Third-trimester use may cause neonatal adrenal suppression, transient growth retardation, and immunosuppression. Monitor neonate. |
Clinical note
Comprehensive clinical and safety monograph for PREDNICEN-M (PREDNICEN-M).
| Placental transfer | Prednisolone crosses the placenta; however, placental 11β-HSD2 converts prednisolone to inactive prednisone, limiting fetal exposure to ~10-20% of maternal concentration. Higher transfer occurs with prednisone. |
| Breastfeeding | Prednisolone enters breast milk in low concentrations (milk:plasma ratio 0.1-0.2). At maternal doses up to 80 mg/day, infant exposure is <10% of maternal weight-adjusted dose. Consider waiting 4 hours after dosing to breastfeed to reduce exposure. |
■ FDA Black Box Warning
No FDA black box warning specifically for Prednicen-M. However, corticosteroids in general carry warnings for immunosuppression, increased susceptibility to infections, and risk of adrenal suppression upon withdrawal.
| Serious Effects |
Systemic fungal infectionHypersensitivity to prednisone or any componentAdministration of live or live-attenuated vaccines (immunosuppression risk)Idiopathic thrombocytopenic purpura (IM route contraindicated)
| Precautions | Adrenal suppression: Avoid abrupt withdrawal; taper dose., Immunosuppression: Increased risk of infections; avoid live vaccines., Osteoporosis: Long-term use may cause bone loss., GI effects: Increased risk of peptic ulcers; use with caution in ulcerative colitis., Ocular effects: May cause glaucoma or cataracts., Fluid/electrolyte disturbances: May cause sodium retention, potassium loss., Psychiatric effects: May cause mood swings, euphoria, or psychosis., Children: May suppress growth., Pregnancy: Fetal risk; weigh benefits vs risks. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as it may increase prednisone levels. Limit sodium intake to reduce fluid retention. Avoid alcohol due to increased risk of gastrointestinal irritation with corticosteroids. |
Loading safety data…
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | First trimester: Increased risk of cleft palate (odds ratio 3.35). Second/third trimester: Fetal adrenal suppression, intrauterine growth restriction, oligohydramnios with prolonged use. Risk outweighs benefits unless maternal condition requires therapy. |
| Fetal Monitoring | Maternal: Blood glucose, blood pressure, bone density, ocular pressure. Fetal: Ultrasound for growth restriction and amniotic fluid volume if prolonged use. Neonatal: Assess for adrenal insufficiency if maternal use in late pregnancy. |
| Fertility Effects | May alter menstrual cycle or inhibit ovulation via suppression of gonadotropins. Reversible upon dose reduction or discontinuation. No conclusive evidence of permanent impairment. |
| Clinical Pearls | Prednicen-M is a combination product containing prednisone (corticosteroid) and chlorpheniramine maleate (antihistamine). Avoid abrupt discontinuation after prolonged use; taper dose. Monitor for hyperglycemia, osteoporosis, and adrenal suppression. Use cautiously in patients with hypertension, diabetes, or peptic ulcer disease. Antihistamine component may cause sedation; avoid driving or operating machinery. |
| Patient Advice | Take with food or milk to reduce stomach upset. · Do not stop taking this medication suddenly; follow doctor's tapering schedule. · Avoid alcohol and grapefruit juice while on this medication. · Report any unusual weight gain, swelling, or vision changes promptly. · May cause drowsiness; avoid activities requiring alertness until you know how it affects you. |